- Home
- DRDB vs NGNE Comparison
DRDB vs NGNE Comparison
Compare DRDB & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DRDB | NGNE |
|---|---|---|
| Founded | 2024 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.8M | 327.8M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | DRDB | NGNE |
|---|---|---|
| Price | $10.43 | $17.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $38.50 |
| AVG Volume (30 Days) | 16.3K | ★ 179.7K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $596.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.87 | $6.88 |
| 52 Week High | $10.47 | $37.27 |
Technical Indicators
Market Signals| Indicator | DRDB | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 60.21 | 34.70 |
| Support Level | $10.42 | $18.13 |
| Resistance Level | $10.45 | $19.13 |
| Average True Range (ATR) | 0.01 | 1.36 |
| MACD | 0.00 | -0.16 |
| Stochastic Oscillator | 100.00 | 7.82 |
Price Performance
Historical ComparisonAbout DRDB Roman DBDR Acquisition Corp. II Ordinary shares
Roman DBDR Acquisition Corp II is a blank check company.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.